WOCKHARDT
GenericsWOCKHARDT is a generic drug manufacturer focused on Infectious Disease, Metabolic, Gastroenterology.
WOCKHARDT at a Glance
- Fast trial execution (5 months median completion)
WOCKHARDT's Key Drugs
WOCKHARDT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
WOCKHARDT's Recent FDA Approvals
WOCKHARDT secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
WOCKHARDT's Therapeutic Areas
WOCKHARDT's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.
WOCKHARDT's Top Competitors
WOCKHARDT's closest competitors by therapeutic-area and drug-target overlap include Merck, PHARMACIA AND UPJOHN, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
WOCKHARDT Pipeline Snapshot
WOCKHARDT has 16 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 1 Phase 2 and 10 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/4 completed
- • Speed: 5 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 1979-02-26
- Latest
- 2020-05-10
- Applications
- 46
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges